Vera Therapeutics, Inc. (VERA) stock
VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
$28.10−0.94 (-3.24%)
Close on Nov 13, 2026Market cap $2.02BP/E –Yield –
Vera Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Vera Therapeutics's total assets was $465.75M at Sep 30, 2026. For fiscal 2025 it was $734.73M, up 12.1% from the year before. The highest annual figure on record is $734.73M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $734.73M | +12.1% |
| FY2024 | Dec 31, 2024 | $655.68M | +273.5% |
| FY2023 | Dec 31, 2023 | $175.55M | +33.6% |
| FY2022 | Dec 31, 2022 | $131.44M | +56.9% |
| FY2021 | Dec 31, 2021 | $83.75M | +53.5% |
| FY2020 | Dec 31, 2020 | $54.55M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $465.75M | -10.0% |
| Q2 FY2026 | Jun 30, 2026 | $532.98M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $621.74M | +1.9% |
| Q4 FY2025 | Dec 31, 2025 | $734.73M | +12.1% |
| Q3 FY2025 | Sep 30, 2025 | $517.50M | +40.4% |
| Q2 FY2025 | Jun 30, 2025 | $578.53M | +45.6% |
| Q1 FY2025 | Mar 31, 2025 | $610.17M | +45.5% |
| Q4 FY2024 | Dec 31, 2024 | $655.68M | +273.5% |
| Q3 FY2024 | Sep 30, 2024 | $368.56M | +109.9% |
| Q2 FY2024 | Jun 30, 2024 | $397.29M | +103.6% |
| Q1 FY2024 | Mar 31, 2024 | $419.36M | +100.1% |
| Q4 FY2023 | Dec 31, 2023 | $175.55M | +33.6% |
| Q3 FY2023 | Sep 30, 2023 | $175.62M | +33.7% |
| Q2 FY2023 | Jun 30, 2023 | $195.18M | +31.2% |
| Q1 FY2023 | Mar 31, 2023 | $209.60M | +27.1% |
| Q4 FY2022 | Dec 31, 2022 | $131.44M | +56.9% |
| Q3 FY2022 | Sep 30, 2022 | $131.37M | +44.1% |
| Q2 FY2022 | Jun 30, 2022 | $148.78M | +52.4% |
| Q1 FY2022 | Mar 31, 2022 | $164.97M | +218.3% |
| Q4 FY2021 | Dec 31, 2021 | $83.75M | +53.5% |
| Q3 FY2021 | Sep 30, 2021 | $91.17M | – |
| Q2 FY2021 | Jun 30, 2021 | $97.65M | – |
| Q1 FY2021 | Mar 31, 2021 | $51.83M | – |
| Q4 FY2020 | Dec 31, 2020 | $54.55M | – |
See a number that looks wrong?